GlaxoSmithKline Plc has signed an agreement with a service company in Germany to gain access to technology for industrialising cell and gene therapies. The two parties will also discover new chimeric antigen-receptor T (CAR T) cell therapies. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Regenerative Medicine
